Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

The number of participants at each demographic category: sex, race and ethnicity

Number of participants at each Eastern Cooperative Oncology Group (ECOG) performance status, comorbidities, and GI symptoms

Participants' average body mass index (BMI) in kilogram per square meters

Participants' average body surface area (BSA) in square meters

Average Ejection Fraction (EF) and Left Ventricular Ejection Fraction (LVEF) as determined by ECHO or MUGA reported as a percentage

Number of participants at each initial diagnosis stage, TNM (tumor, nodes and metastasis) and clinical staging (metastatic, locally advanced, unresectable), disease subtype (gastric, esophageal or gastroesophageal) and metastatic sites by location

Treatment history will be defined as the number of participants with previous surgical resection, and adjuvant or neoadjuvant treatments

Number of participants at each PDL-1 expression category (through tumor area positivity (TAP) and combined positive score (CPS) scoring), HER2 amplification and expression results status via immunohistochemistry (IHC) or next generation sequencing (NGS).

Number of participants who took chemotherapy or immunotherapy in combination with first line zanidatamab-containing therapy

The average dose of zanidatamab per cycle and first line zanidatamab-containing therapy

Number of planned cycles of first line zanidatamab-containing therapy and actual number of cycles of first line zanidatamab-containing therapy

Number of participants at each reason for treatment discontinuation, interruption and/or chemotherapy dose adjustment

Incidence of adverse events of special interest (AESI), including diarrhea, associated with programmed cell death protein 1 (PD-1) antagonists

Duration of the AESI, including the first and subsequent incidence of diarrhea

Time (by treatment cycle) where the onset of AESI and the first and following incidences of diarrhea occurred

Time (by treatment cycle) adjustment for chemotherapy, immunotherapy agent or zanidatamab due to diarrhea and AESI

Time of dose (by treatment cycle) where supportive therapy for AESI and additional therapy for diarrhea was initiated

Number of participants at each category of causality of AESI, including diarrhea

Number of participants at each category of resolution of AESI, including diarrhea

Number of participants that had to initiate additional supportive therapy due to AESI and/or diarrhea

Number of new metastatic site by location

rwORR is defined as the proportion of participants with a best overall response of Complete Response (CR) or Partial Response (PR) to 1L zanidatamab-containing therapy

rwR will be reported as real-world complete response (rwCR) which is the proportion of participants with complete clearance of tumor and real-world partial response (rwPR) which is the proportion of participants with reduced tumor burden

rwP is defined as the proportion of participants with clinician documentation or radiologic evidence of disease worsening

rwPFS is defined as the time (in months) from the initiation of 1L zanidatamab-containing therapy until the first occurrence of documented disease progression or death

rwPFS2 is defined as the time (in months) from the initiation of 1L zanidatamab-containing therapy until the date of first documented disease progression on the subsequent line of therapy, or death, whichever occurs first

rwDoR is defined as the time (in months) from first real world CR or real world PR to the first documented real world disease progression or death

Overall survival (OS) is defined as the time (in months) from the initiation of 1L zanidatamab-containing therapy until death

European Organization for Research and Treatment of Cancer (EORTC) Item Library 66 (EORTC IL 66) includes EORTC Item library 19 (EORTC IL 19) and EORTC global health status (GHS)/quality of life (QoL) (EORTC GHS/QoL).

EORTC IL 19 is a 5-item scale that assesses the physical functioning domain of health-related quality of life (HRQoL). It has a total score ranging from 0 to 100 with a higher score indicating better level of physical functioning.

EORTC GHS/QoL is a 2-item scale with a total score ranging from 0 to 100 with a higher score indicating better level of overall well-being and HRQoL.